fbpx

List – 54 Drug Patents that are Expiring in 2024

In our last article, we discussed the drug patents expiring in 2023. We are mid-way to 2022 and we like to stay on top of the data. You too?

Well, if you are from the pharma domain, working on the development of generics, you have got to!

With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 54 drugs that are going off-patent in 2024. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the drug most profitable to develop a generic version. 

Loved the idea and the list? Thank us later in the comments section. Now onto the list.

The article has a list of drug patents expiring in 2024. If you want to get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.


Drug Patents Expiring in 2024

Mulpleta
Lusutrombopag

Sales:
200 Million Yen (2018)

More information about this Drug

Patents Expiration Date
US7601746 September 05, 2024
US8889722 July 29, 2028
US8530668 January 21, 2030

Dosage: Oral
Company: Shionogi Inc.
Ingredients: LUSUTROMBOPAG
Treatment: Thrombocytopenia

Invokamet XR
Canagliflozin; Metformin Hydrochloride

Sales:
$1.41 Billion (2016)

More information about this Drug

Patents Expiration Date
US8785403 July 30, 2024
US8222219 March 11, 2025

Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus

Revlimid
Lenalidomide

Sales:
$10.82 Billion (2019)

More information about this Drug

Patents Expiration Date
US7855217 November 24, 2024
US7465800 April 27, 2027

Dosage: Oral
Company: Celgene Corp
Ingredients: LENALIDOMIDE
Treatment: Multiple Myeloma and Myelodysplastic Syndromes

Rydapt
Midostaurin

Sales:
$150 Million (2018)

More information about this Drug

Patents Expiration Date
US7973031 October 17, 2024
US8222244 October 29, 2022

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia

Prevymis
Letermovir

Sales:
$370 Million (2020)

More information about this Drug

Patents Expiration Date
US7196086 May 22, 2024
US8513255 May 22, 2024

Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection

Vyndaqel
Tafamidis Meglumine

Sales:
$259 Million (Jan-Sep 2019)

More information about this Drug

Patents Expiration Date
US7214695 April 27, 2024
US7214696 December 19, 2023
US8168663 December 19, 2023
US8653119 January 28, 2024

Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy

Lynparza
Olaparib

Sales:
$847 Million (2018)

More information about this Drug

Patents Expiration Date
US7151102 April 29, 2022
US7449464 October 11, 2024
US7981889 October 11, 2024
US8912187 March 12, 2024

Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer

Tasigna
Nilotinib

Sales:
$1.88 Billion (2019)

More information about this Drug

Patents Expiration Date
US7169791 January 04, 2024
US8415363 January 18, 2027
US8163904 February 23, 2029
US9061029 October 7, 2032

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia

Xopenex HFA
Levalbuterol Tartrate

Sales:
$148 Million (2012)

More information about this Drug

Patents Expiration Date
US7256310 October 08, 2024

Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Vandazole
Metronidazole

Sales:

More information about this Drug

Patents Expiration Date
US7456207 September 22, 2024

Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis

Prialt
Ziconotide Acetate

Sales:
$27 Million (2017)

More information about this Drug

Patents Expiration Date
US8653033 October 10, 2024
US8765680 October 10, 2024
US9707270 October 10, 2024

Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever

Aloxi
Palonosetron Hydrochloride

Sales:
$400 Million (2019)

More information about this Drug

Patents Expiration Date
US7947724 January 30, 2024
US7947725 January 30, 2024
US7960424 January 30, 2024
US8518981 January 30, 2024
US8598218 January 30, 2024
US9173942 January 30, 2024
US9439854 January 30, 2024
US9457020 January 30, 2024

Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting

Dificid
Fidaxomicin

Sales:
$60 Million (2021)

More information about this Drug

Patents Expiration Date
US8586551 January 23, 2024
US7378508 January 31, 2028
US7863249 January 31, 2028

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: FIDAXOMICIN
Treatment: Clostridioides difficile-associated Diarrhea (CDAD)

Linzess
Linaclotide

Sales:
$287 Million (2021)

More information about this Drug

Patents Expiration Date
US7371727 January 28, 2024
US7745409 January 28, 2024
US8080526 January 28, 2024
US7704947 January 28, 2024
US7304036 August 30, 2026

Dosage: Oral
Company: Allergan
Ingredients: LINACLOTIDE
Treatment: Irritable Bowel Syndrome

Myfembree
Relugolix/estradiol/norethisterone acetate

Sales:

More information about this Drug

Patents Expiration Date
US7300935 January 28, 2024
US8058280 January 28, 2024

Dosage: Oral
Company: Myovant Sciences
Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Treatment: Heavy Menstrual Bleeding

Ferric Citrate
Ferric Citrate

Sales:

More information about this Drug

Patents Expiration Date
US9328133 February 18, 2024
US9757416 February 18, 2024
US8338642 February 18, 2024
US7767851 February 18, 2024

Dosage: Oral
Company: Akebia Therapeutics
Ingredients: FERRIC CITRATE
Treatment: Hyperphosphataemia and Iron Deficiency Anaemia

Ofev/Vargatef
Nintedanib

Sales:

More information about this Drug

Patents Expiration Date
US7119093 February 21, 2024
US6762180 October 1, 2025

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: NINTEDANIB ESYLATE
Treatment: Idiopathic Pulmonary Fibrosis

Isentress
Raltegravir

Sales:
$857 Million (2020)

More information about this Drug

Patents Expiration Date
US7119093 February 21, 2024
US6762180 October 1, 2025

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS

Zontivity
Vorapaxar

Sales:

More information about this Drug

Patents Expiration Date
US7304078 April 6, 2024
US7713999 May 30, 2024

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: VORAPAXAR SULFATE
Treatment: Peripheral Arterial Disease

Bosulif
Bosutinib

Sales:
$23 Million (2020)

More information about this Drug

Patents Expiration Date
USRE42376 April 13, 2024
US7767678 November 23, 2026

Dosage: Oral
Company: Pfizer
Ingredients: BOSUTINIB MONOHYDRATE
Treatment: Chronic Myelogenous Leukemia

Omontys
Peginesatide

Sales:

More information about this Drug

Patents Expiration Date
US7084245 May 12, 2024
US7414105 May 12, 2024
US7919118 May 12, 2024
US7528104 May 12, 2024

Dosage: Subcutaneous, intravenous
Company: Affymax Inc.
Ingredients: PEGINESATIDE ACETATE
Treatment: Anemia

Aliqopa
Copanlisib

Sales:

More information about this Drug

Patents Expiration Date
US7511041 May 13, 2024
USRE46856 October 22, 2029
US10383876 March 29, 2032

Dosage: Intravenous infusion
Company: Bayer
Ingredients: COPANLISIB DIHYDROCHLORIDE
Treatment: Relapsed follicular lymphoma

Mayzent
Siponimod

Sales:

More information about this Drug

Patents Expiration Date
US7939519 May 19, 2024

Dosage: Oral
Company: Novartis
Ingredients: SIPONIMOD FUMARIC ACID
Treatment: Multiple Sclerosis

Prevymis
Letermovir

Sales:
$281 Million (2020)

More information about this Drug

Patents Expiration Date
US8513255 May 22, 2024
USRE46791 May 22, 2024

Dosage: Oral, Intravenous
Company: Merck & Co
Ingredients: LETERMOVIR
Treatment: Cytomegalovirus

Xifaxan
Rifaximin

Sales:

More information about this Drug

Patents Expiration Date
US7612199 June 19, 2024
US8835452 June 19, 2024
US8158781 June 19, 2024
US7045620 June 19, 2024
US7902206 June 19, 2024
US7906542 June 1, 2025
US8741904 February 27, 2026
US8193196 September 2, 2027

Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: RIFAXIMIN
Treatment: Travelers’ Diarrhea, Irritable Bowel Syndrome

Remodulin/Orenitram/Tyvaso
Treprostinil

Sales:

More information about this Drug

Patents Expiration Date
US9050311 May 24, 2024
US7417070 July 30, 2026
US8497393 December 15, 2028

Dosage: Subcutaneous, intravenous, inhalation, Oral
Company: United Therapeutics
Ingredients: TREPROSTINIL DIOLAMINE
Treatment: Pulmonary arterial hypertension

Tpoxx
Tecovirimat

Sales:

More information about this Drug

Patents Expiration Date
US8124643 June 18, 2024
US9339466 March 23, 2031

Dosage: Oral
Company: SIGA Technologies
Ingredients: TECOVIRIMAT
Treatment: Orthopoxviruses (Smallpox and Monkeypox)

Nuvigil
Armodafinil

Sales:

More information about this Drug

Patents Expiration Date
US7132570 June 18, 2024

Dosage: Oral
Company: Teva Pharmaceuticals
Ingredients: ARMODAFINIL
Treatment: Excessive Daytime Sleepiness

Oriahnn
Elagolix/estradiol/norethindrone acetate

Sales:
$145 Million (2021)

More information about this Drug

Patents Expiration Date
US7419983 July 6, 2024
US7056927 September 10, 2024

Dosage: Oral
Company: AbbVie Inc.
Ingredients: ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
Treatment: Heavy Menstrual Bleeding

Xeglyze
Abametapir

Sales:

More information about this Drug

Patents Expiration Date
US9839631 July 16, 2024

Dosage: Topical
Company: Dr. Reddy’s Laboratories
Ingredients: ABAMETAPIR
Treatment: Head Lice Infestation

Ninlaro
Ixazomib

Sales:

More information about this Drug

Patents Expiration Date
US8546608 August 12, 2024
US8003819 August 6, 2027
US8530694 August 6, 2027
US7687662 August 6, 2027
US8859504 June 16, 2029
US7442830 November 20, 2029

Dosage: Oral
Company: Takeda
Ingredients: IXAZOMIB CITRATE
Treatment: Multiple Myeloma

Prezista
Darunavir

Sales:

More information about this Drug

Patents Expiration Date
US8518987 August 16, 2024
US7700645 June 26, 2027

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: DARUNAVIR
Treatment: HIV/AIDS

Xarelto
Rivaroxaban

Sales:

More information about this Drug

Patents Expiration Date
US7157456 August 28, 2024

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: RIVAROXABAN
Treatment: Blood clots

MoviPrep
POLYETHYLENE GLYCOL 3350

Sales:

More information about this Drug

Patents Expiration Date
US7169381 September 1, 2024
US7658914 September 1, 2024

Dosage: Oral
Company: Velinor A.G
Ingredients: ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Treatment: Use for Colonoscopy Bowel Preparation

Aldara
Imiquimod

Sales:

More information about this Drug

Patents Expiration Date
US7696159 October 1, 2024

Dosage: Topical
Company: 3M Pharmaceutical
Ingredients: IMIQUIMOD
Treatment: Genital Warts, Superficial Basal cell carcinoma, and Actinic Keratosis

Brilinta
Ticagrelor

Sales:
$1.4 Billion (2021)

More information about this Drug

Patents Expiration Date
USRE46276 October 30, 2024

Dosage: Oral
Company: AstraZeneca
Ingredients: TICAGRELOR
Treatment: Stroke, Heart Attack

Xiidra
Lifitegrast

Sales:

More information about this Drug

Patents Expiration Date
US7745460 November 5, 2024
US7928122 November 5, 2024
US7314938 March 10, 2025
US8084047 May 17, 2026
US9890141 October 21, 2030

Dosage: Eye Drops
Company: Novartis
Ingredients: LIFITEGRAST
Treatment: Signs and Symptoms of Dry Eye

Nourianz
Istradefylline

Sales:

More information about this Drug

Patents Expiration Date
US7541363 November 13, 2024

Dosage: Oral
Company: Kyowa Kirin Co.
Ingredients: ISTRADEFYLLINE
Treatment: Levodopa/Carbidopa in adults with Parkinson’s disease

Ponvory
Ponesimod

Sales:

More information about this Drug

Patents Expiration Date
USRE43728 November 16, 2024
US9062014 May 6, 2032

Dosage: Oral
Company: Janssen Pharmaceuticals
Ingredients: PONESIMOD
Treatment: Multiple Sclerosis

Tukysa
Tucatinib

Sales:

More information about this Drug

Patents Expiration Date
US7452895 November 16, 2024
US8648087 April 12, 2031

Dosage: Oral
Company: Seagen Inc
Ingredients: TUCATINIB
Treatment: HER2-positive Breast Cancer

Asclera/Aethoxysklerol/Varithena
Polidocanol

Sales:

More information about this Drug

Patents Expiration Date
US7731986 November 17, 2024

Dosage: Topical, Subcutaneous Injection
Company: Methapharm, Inc.
Ingredients: POLIDOCANOL
Treatment: Itching caused by Eczema and Dry Skin

Zepzelca
Lurbinectedin

Sales:

More information about this Drug

Patents Expiration Date
US7763615 December 13, 2024

Dosage: Intravenous Injection
Company: PharmaMar, S.A.
Ingredients: LURBINECTEDIN
Treatment: Metastatic Small Cell Lung Cancer (SCLC)

Victrelis
Boceprevir

Sales:

More information about this Drug

Patents Expiration Date
USRE43298 December 22, 2024

Dosage: Oral
Company: Merck & Co
Ingredients: BOCEPREVIR
Treatment: Hepatitis caused by Hepatitis C virus (HCV) genotype 1

Conclusion

As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version. 

With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.


Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team

Leave a Comment